Le Lézard
Classified in: Health
Subjects: PDT, FDA

Novadoz Pharmaceuticals/MSN Labs gains FDA approval and commences shipping of Pregabalin capsules, the largest generic product launch of the year

PISCATAWAY, N.J., July 23, 2019 /PRNewswire/ -- Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of Pregabalin capsules on July 19th.  The patent expiration for the brand Lyrica© marketed by Pfizer, occurred on that day which cleared the way for the company to begin immediate shipping of the product.   


Novadoz Pregabalin capsules are available in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg strength capsules in 90 count bottles, with bulk sizes slated for post launch. Pregabalin is indicated for epilepsyneuropathic painfibromyalgia, and restless leg syndrome. Its use to treat epilepsy as adjunctive therapy for partial seizures. The brand is currently trending over $5.4 BIL USD in published annual sales.   

Seshu Akula, Novadoz President North America Generics, was quoted, "The approval for Pregabalin, one of the largest generic industry launches in past several years, was a tremendous accomplishment for our entire organization.  This product will be an important one for Novadoz over the next decade, providing a steady revenue stream while defining our company's ability to be a consistent and reliable supplier to our customers.  We are anticipating an additional 10 to 12 product launches over the next 18 months, that continues the bright outlook we have on our future in the U.S market."

Novadoz's, Tom DeStefano, Vice President Sales & Marketing states, "Novadoz's entrance as a DAY 1 supplier of Pregabalin, further elevates our company's status as a generic supplier.  The scope and size of the product requires a highly efficient and well-planned supply chain and manufacturing process.  MSN brings this level of competency to this launch, as well as supporting our current business and future product introductions."

MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates.  MSN is recognized as a global leader in this category.  In addition, the company manufactures finished dosage oral solids, liquids, and injectable products in sixty-five markets throughout the world, doing business in the U.S under the Novadoz label.

For more information, visit the company's websites at www.NovadozPharma.comwww.MSNLabs.com

Tom DeStefano
Novadoz Pharmaceuticals
Vice President Sales and Marketing
(908) 360-1500, ext. 507

SOURCE Novadoz Pharmaceuticals

These press releases may also interest you

at 04:00
StatLab Medical Products is pleased to announce the receipt of patent No. 10,329,623, a novel method for development of an improved tissue-like control created by Dr. S. Ashraf Imam, Director of Advanced Diagnostics Research and Development at...

at 03:55
Just in time for World Alzheimer's Day, a group of young activists in their 20's have created a nationwide call to action for presidential candidates to take action on Alzheimer's disease. Spearheaded by The Youth Movement Against Alzheimer's...

at 03:00
What can be said of people who would rather be feared than be loved? Perhaps they get a thrill out of making others feel weak and inferior, or think that having others cower is the fastest way to power. However, if history has taught the world...

at 03:00
NJ Top Docs has reviewed and approved Lisa Silbret, MD and Alan Schechter, MD for 2019. These board certified dermatologists practice in Manalapan, New Jersey which is located in Monmouth County. At Dr. Silbret and Dr. Schechter's office, they...

at 03:00
Dr. Perry Patel, an Arroyo Grande dentist, recently announced that he has been certified by the American Academy of Facial Esthetics (AAFE) to administer dermal filler injections. Dr. Patel offers Juvederm® dermal fillers and SkinMedica® professional...

at 02:00
Chronic kidney disease affects 1 out of 10 people worldwide and is steadily increasing. When it reaches end-stage renal disease and endangers the lives of patients, dialysis or transplantation is required. Renal transplantation is the treatment of...

News published on 23 july 2019 at 13:29 and distributed by: